Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Langerhans cell histiocytosis case with dense metaphyseal band sign.

Kikkawa I, Aihara T, Morimoto A, Watanabe H, Furukawa R.

Pediatr Int. 2013 Feb;55(1):96-8. doi: 10.1111/j.1442-200X.2012.03618.x.

PMID:
23409985
2.

Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.

Sivendran S, Harvey H, Lipton A, Drabick J.

Int J Hematol. 2011 Jun;93(6):782-6. doi: 10.1007/s12185-011-0839-2. Epub 2011 Apr 26.

PMID:
21519845
3.

Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.

Montella L, Merola C, Merola G, Petillo L, Palmieri G.

J Bone Miner Metab. 2009;27(1):110-3. doi: 10.1007/s00774-008-0001-2. Epub 2008 Nov 19.

PMID:
19018458
5.

Osteochondritis (Calvé's disease) of a vertebral body--a rare form of vertebra plana.

Shisha T, Kiss S, Varga PP, Bucsi L, Pap K, Szoke G.

Eur Spine J. 2006 Mar;15(3):377-83. Epub 2005 Aug 13.

6.

Langerhans cell histiocytosis of spine: a comparative study of clinical, imaging features, and diagnosis in children, adolescents, and adults.

Huang WD, Yang XH, Wu ZP, Huang Q, Xiao JR, Yang MS, Zhou ZH, Yan WJ, Song DW, Liu TL, Jia NY.

Spine J. 2013 Sep;13(9):1108-17. doi: 10.1016/j.spinee.2013.03.013. Epub 2013 Apr 18.

PMID:
23602327
7.

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.

Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

8.

Surgical treatment based on pedicle screw instrumentation for thoracic or lumbar spinal Langerhans cell histiocytosis complicated with neurologic deficit in children.

Lü GH, Li J, Wang XB, Wang B, Phan K.

Spine J. 2014 May 1;14(5):768-76. doi: 10.1016/j.spinee.2013.06.104. Epub 2013 Sep 12.

PMID:
24035731
9.

Seizures associated with zoledronic acid for osteoporosis.

Tsourdi E, Rachner TD, Gruber M, Hamann C, Ziemssen T, Hofbauer LC.

J Clin Endocrinol Metab. 2011 Jul;96(7):1955-9. doi: 10.1210/jc.2011-0418. Epub 2011 Apr 20.

PMID:
21508139
10.

Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate.

Hospach T, Langendoerfer M, von Kalle T, Maier J, Dannecker GE.

Eur J Pediatr. 2010 Sep;169(9):1105-11. doi: 10.1007/s00431-010-1188-5. Epub 2010 Mar 27.

PMID:
20339868
11.

[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].

Dong M, Feng FY, Zhang Y, Xie GR, Wang YJ, Liu JW, Song ST, Zhou QH, Ren J, Jiao SC, Li J, Wang XW, Chen Q, Wang ZH, Xu N, Feng JF.

Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):215-20. Chinese.

PMID:
18756940
12.

[A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient].

Okagawa Y, Sato Y, Onuma H, Osuga T, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Kato J.

Gan To Kagaku Ryoho. 2015 Jul;42(7):867-70. Japanese.

PMID:
26197752
13.

[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

Dalle Carbonare L, Bertoldo F, Lo Cascio V.

Reumatismo. 2009 Jan-Mar;61(1):54-64. Italian.

14.

Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A.

Wien Klin Wochenschr. 2006 Aug;118(15-16):473-8.

PMID:
16957978
15.

Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy.

Cornelis F, Truchetet ME, Amoretti N, Verdier D, Fournier C, Pillet O, Gille O, Hauger O.

Bone. 2014 Jan;58:11-6. doi: 10.1016/j.bone.2013.10.004. Epub 2013 Oct 11.

PMID:
24120668
16.

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y.

Cancer J. 2001 Sep-Oct;7(5):377-87.

PMID:
11693896
17.

Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction.

Wu D, Ma J, Bao S, Guan H.

Rheumatol Int. 2015 Apr;35(4):767-72. doi: 10.1007/s00296-014-3132-x. Epub 2014 Sep 18.

PMID:
25230905
18.

Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer.

El Saghir NS, Otrock ZK, Bleik JH.

BMC Cancer. 2005 Dec 6;5:156.

19.

Zoledronic acid and clinical fractures and mortality after hip fracture.

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial.

N Engl J Med. 2007 Nov 1;357(18):1799-809. Epub 2007 Sep 17.

20.

Fracture risk and zoledronic acid therapy in men with osteoporosis.

Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.

N Engl J Med. 2012 Nov;367(18):1714-23. doi: 10.1056/NEJMoa1204061.

Items per page

Supplemental Content

Write to the Help Desk